On the morning of April 21, 2026, DHG Pharma successfully held its 2025 Annual General Meeting of Shareholders (AGM) in Can Tho City, with the participation of a large number of shareholders, the Board of Directors, and the Executive Management. The shareholder attendance rate reached a high level, demonstrating investors’ strong interest in and commitment to the company’s development strategy.
Approval of key corporate governance matters
At AGM, Mr. Toshifumi Kojima – Acting Chief Executive Officer, presented a detailed report on the company’s business performance in 2025 and its plan for 2026. Subsequently, Mr. Đỗ Lê Hùng – Independent Member of the Board of Directors and Chairman of the Audit Committee, delivered a report on governance oversight, transparency in financial reporting, and the effectiveness of the internal control system over the past year.
Shareholders discussed and voted to approve several key matters, including the 2025 audited financial statements, the profit distribution plan, the appointment of the auditing firm for 2026, and amendments and supplements to the Company Charter and internal governance regulations.
Regarding personnel matters, the General Meeting of Shareholders carried out the procedures for dismissal and the election of Ms. Sawa Sawada as an additional member of the Board of Directors for the remainder of Term V (2024–2028).
“A passport” to global standards
A major milestone highlighted at the Meeting was the Betalactam Plant officially achieving EU‑GMP certification on September 2, 2025. With this achievement, DHG Pharma has become one of Vietnam’s leading pharmaceutical companies to concurrently hold the world’s two most stringent standards: Japan‑GMP and EU‑GMP. This serves as a solid foundation for the company to expand its export markets, enhance its competitive capabilities, and affirm its international position.
Business performance in 2025: Proof of a flexible and decisive management strategy
The year 2025 marked an impressive business performance for DHG Pharma, as the company met and exceeded all targets assigned by the General Meeting of Shareholders. Net revenue reached VND 5,267 billion, fulfilling 101% of the plan and growing 8% compared to 2024. Profit before tax amounted to VND 987 billion, achieving 105% of the plan and increasing 9% year on year. These results enabled DHG Pharma to continue maintaining its leading position in Vietnam’s pharmaceutical industry for the 29th consecutive year in both revenue and profit.
This strong performance was driven primarily by positive growth in the domestic market, with particularly notable momentum in the modern retail channel. Thanks to the stable contribution of strategic product groups such as Hapacol, Klamentin, and Apitim, together with production capacity maintained at a high scale, DHG Pharma continued to consolidate its leading position in the retail channel and remained among the pharmaceutical companies with the largest market share in Vietnam.
Plan to Achieve the Trillion‑VND Profit Milestone in 2026
The General Meeting also approved targets of VND 5,530 billion in net revenue and VND 1,007 billion in profit before tax, clearly reflecting a sustainable growth orientation closely linked with digital transformation.
To achieve these objectives, the company will focus on optimizing internationally standardized manufacturing capabilities, strengthening the modern retail channel, and positioning the OEM strategy as a new growth pillar. In parallel, DHG Pharma will intensify R&D activities, promote technology transfer, and accelerate new product registrations to diversify its portfolio, enhance competitiveness, and expand market presence.
In addition, with a steadfast commitment to quality and transparency in governance, DHG Pharma will prioritize strengthening its succession team and fostering a culture of early risk management to ensure sustainable development and protect long‑term shareholder interests during the 2026–2030 period. The company continues to reinforce the DHG Pharma brand – “For a more beautiful and healthier life”, aiming to deliver sustainable value and long‑term growth for shareholders and the community.
DHG Pharma’s Annual General Meeting of Shareholders 2025 was held on the morning of April 21, 2026, at Charmant Suites Hotel, Can Tho City.
Representatives of the Board of Management attending the General Meeting
Atmosphere outside the General Meeting
Overview of shareholders raising voting ballots at the AGM
At the General Meeting, Mr. Do Le Hung – Independent Member of the Board of Directors and Chairman of the Audit Committee – presented the 2025 Activity Report of the Audit Committee and the Independent Board Member serving on the Audit Committee.
